Health Canada has approved TALTZĀ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Go back to Health Canada has approved TALTZĀ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1273.46 -33.23 (2.54%)
Previous Close $1306.69    52 Week High $88.16 
Open $1304.15    52 Week Low $67.88 
Day High $1307.92    P/E 294.78 
Day Low $1257.62    EPS $4.32 
Volume 2,277,291